Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gender differences in ED50 and EEG characteristics of remimazolam for anesthesia induction in day surgery
ChiCTR2400079965Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Median effective dose (ED50) of remimazolam for anesthesia induction. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2400079965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079965.